IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Disrupting IL-6 paracrine signaling of can inhibit the activity of BCR/ABL, and IL-6 inhibitors combined with PD-1 inhibitors can have an antitumor effect, thus contributing to the clearance of cancer cells in the CML TME (93, 94).